Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 4Myeloproliferative Disorders 3Leukemia, Biphenotypic, Acute 3Blast Crisis 2Sarcoma, Myeloid 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Specimen Handling 6fludarabine 5Whole-Body Irradiation 5Cytarabine 5Cyclophosphamide 5venetoclax 4Methotrexate 4Biopsy 4merphos 3fludarabine phosphate 3blinatumomab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3prednylidene 2deltacortene 2calaspargase pegol 2Thiotepa 2Tacrolimus 2Stem Cell Transplantation 2Spinal Puncture 2Rituximab 2Prednisone 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Leucovorin 2Filgrastim 2CT-P10 2Busulfan 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × Idarubicin × 30 days × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡